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1020Objectives: The study objective was to evaluate patients with Marfan syndrome and mitral valve regurgitation
undergoing valve repair or replacement and to compare them with patients undergoing repair for myxomatous
mitral valve disease.
Methods: We reviewed the medical records of consecutive patients with Marfan syndrome treated surgically
between March 17, 1960, and September 12, 2011, for mitral regurgitation and performed a subanalysis of those
with repairs compared with case-matched patients with myxomatous mitral valve disease who had repairs
(March 14, 1995, to July 5, 2013).
Results: Of 61 consecutive patients, 40 underwent mitral repair and 21 underwent mitral replacement (mean
[standard deviation] age, 40 [18] vs 31 [19] years; P ¼ .09). Concomitant aortic surgery was performed to a
similar extent (repair, 45% [18/40] vs replacement, 43% [9/21]; P ¼ .87). Ten-year survival was significantly
better in patients with Marfan syndrome with mitral repair than in those with replacement (80% vs 41%;
P ¼ .01). Mitral reintervention did not differ between mitral repair and replacement (cumulative risk of reop-
eration, 27% vs 15%; P ¼ .64). In the matched cohort, 10-year survival after repair was similar for patients
with Marfan syndrome and myxomatous mitral disease (84% vs 78%; P ¼ .63), as was cumulative risk of re-
operation (17% vs 12%; P ¼ .61).
Conclusions: Patients with Marfan syndrome and mitral regurgitation have better survival with repair than with
replacement. Survival and risk of reoperation for patients with Marfan syndrome were similar to those for pa-
tients with myxomatous mitral disease. These results support the use of mitral valve repair in patients with Mar-
fan syndrome and moderate or more mitral regurgitation, including those having composite replacement of the
aortic root. (J Thorac Cardiovasc Surg 2014;148:1020-4)Mitral valve (MV) repair has become the preferredmethod of
surgical treatment for mitral regurgitation (MR). Compared
with replacement, valve repair provides better postoperative
outcomes, including better long-term survival.1 This shift in
surgical practice for MV disease has not been as enthusiasti-
cally embraced in patients with Marfan syndrome (MFS), in
part because of an incomplete mechanistic understanding of
the cause of MV prolapse and resulting MR in this popula-
tion.2 Also, many patients withMFSwho undergo operations
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The Journal of Thoracic and Cardiovascular Suranticoagulation with warfarin; thus, clinicians may prefer
mechanical MV replacement in an attempt to reduce the
risk of future reoperations.
Previous smaller case series suggest that MV repair is du-
rable in patients with MFS3,4; however, durability of repair
remains a concern because of the difference in MV
morphology compared with that in idiopathic
myxomatous MV disease.5 Thus, outcomes of MV repair
in patients with MFS should be interpreted in light of out-
comes of valve replacement and compared with those of pa-
tients having repair for myxomatous MV disease. Our
hypothesis is that MV repair is superior to MV replacement
in patients with MFS with moderate or greater MV regurgi-
tation. Also, outcomes of MV repair in patients with MFS
should be comparable to those of MV repair in patients
with idiopathic myxomatous MV disease.METHODS
After obtaining permission from the Mayo Clinic Institutional Review
Board, we reviewed the medical records of consecutive patients with
MFS who received surgical treatment for MR between March 17, 1960,
and September 12, 2011, at our tertiary care academic medical center.
Data were retrieved from the Mayo Clinic electronic medical record, our
cardiovascular surgical database, and follow-up questionnaires that includegery c September 2014
TABLE 1. Characteristics of 61 patients with Marfan syndrome
undergoing mitral valve surgery
MV repair
(n ¼ 40)
MV replacement
(n ¼ 21) P value
Age, mean (SD), y 40 (18) 31 (19) .09
EF, mean (SD),% 60 (7) 56 (8) .10
Male sex, no. (%) 27 (68) 14 (67) .95
Preoperative NYHA
class III or IV, no. (%)
39 (98) 19 (90) .40
Concomitant aortic
surgery, no. (%)
18 (45) 9 (43) .87
EF, Ejection fraction; MV, mitral valve; NYHA, New York Heart Association; SD,
standard deviation.
Abbreviations and Acronyms
MFS ¼ Marfan syndrome
MR ¼ mitral regurgitation
MV ¼ mitral valve
TGF ¼ transforming growth factor
Helder et al Acquired Cardiovascular Disease
A
C
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patients had signed informed consent forms releasing their medical records
for use in research studies.
All patients undergoing first-time mitral intervention were analyzed,
including those with concomitant aortic surgery. In a subgroup case-
matched analysis, we compared patients with MFS who underwent MV
repair (March 14, 1995, to July 05, 2013) with patients undergoing MV
repair for idiopathic myxomatous MV disease. Patients with MFS were
case-matched 1:2 by sex, ejection fraction (5%), age (5 years), and
date of operation (5 years).
Statistical Analysis
Descriptive statistics are reported, as appropriate, as number (percent-
age) for categoric variables and as mean (standard deviation) or median
(range) for continuous variables. Categoric variables were compared be-
tween the repair group and the replacement group and between matched
repair groups using the chi-square test or Fisher exact test, and continuous
variables were compared using the 2-sample t test or the Wilcoxon rank-
sum test, as appropriate. The Kaplan–Meier method was used to estimate
survival and rates of freedom from reintervention. All statistical tests
were 2-sided, with an alpha level of .05 indicating statistical significance.RESULTS
Entire Patient Cohort
A total of 61 consecutive patients with MFS underwent
surgical treatment for MR during the study period. Forty pa-
tients underwent MV repair, and 21 patients underwent MV
replacement. Case-matching was possible for 32 patients
with MFS, yielding a total of 64 control patients.
Presenting symptoms for the 61 patients with MFS with
MR varied; 85% (n ¼ 51) had dyspnea, 8% (n ¼ 5) had
fatigue, 3% (n ¼ 2) had palpitations, 3% (n ¼ 2) had
angina, and 1% (n ¼ 1) had cardiac arrest. The mean
age of the 61 patients was 37 (9) years; patients who under-
went MV repair were slightly older than those who under-
went MV replacement (mean age, 40 [18] vs 31 [19] years;
P ¼ .09). Other demographic characteristics were similar
between the MV repair and replacement groups (Table
1). Of the 13 patients undergoing MV repair and concom-
itant aortic surgery, 6 had aortic valve-sparing root re-
placements, 1 had an arch replacement, and the rest
(n ¼ 6) had aortic valve replacement and repair of the
aorta. Of the 9 patients who underwent MV replacement
and concomitant aortic surgery, none had valve-sparing
aortic root replacement. Most patients in the repair group
and the replacement group had MR grades greater than 2
(95% in both groups [38/40] and [20/21], respectively).
The percentage of patients receiving anticoagulation
before operation was similar between both groups (20%The Journal of Thoracic and Car[8/40] vs 29% [6/21], respectively). Indications for antico-
agulation were atrial fibrillation or prior mechanical aortic
valve replacement.
Annuloplasty (78% [29/37] posterior; 22% [8/37] com-
plete) was used in most MV repairs (92% [37/40]). Other
repair techniques included triangular or quadrangular leaflet
resection of the posterior leaflet (38% [15/40]), leaflet plica-
tion (15% [6/40]), neochordae insertion (15% [6/40]), com-
missuroplasty (7.5% [3/40]), and Alfieri stitch (2.5% [1/
40]). Five percent of patients (2/40) had primarily anterior
leaflet pathology, 32% of patients (13/40) had bileaflet pro-
lapse, and 62% of patients (25/40) had primarily posterior
leaflet pathology. Mechanical prostheses were used in 20 of
the 21 patients who underwent MV replacement. The native
MV was completely excised in 38% of patients (8/21).
One early death (1.6% [1/61]) occurred in a patient
undergoing isolated MV replacement in 1981. Nonfatal
in-hospital morbidity included bleeding that required rester-
notomy (6.6% [4/61]), transient ischemic attacks (6.6%
[4/61]), atrial fibrillation (4.9% [3/61]), and prolonged
ventilator support (1.6% [1/61]). Complication rates were
not significantly different between the repair and replace-
ment groups (P ¼ .14).
The mean duration of follow-up was 7 (5) years after MV
repair and 12 (8) years after initial MV replacement
(P ¼ .14). Ten-year survival was significantly better in pa-
tients with MFS undergoing repair versus replacement
(80% vs 41%; P ¼ .01). In the subgroup of patients who
underwent concomitant aortic surgery, 10-year survival
was 64% in patients undergoing repair and 49% in patients
undergoing MV replacement (P ¼ .27) (Figure 1).
In the group with initial MV repair (n ¼ 40), 8 patients
underwent reoperation with MV replacement. Two of these
reoperations occurred in the early experience (1960 and
1966) of Mayo Clinic, and in both cases, initial MV repair
was performed with leaflet sutures only. One patient had
MV replacement for moderate MV regurgitation at the
time of replacement of a calcified aortic valve homograft
with severe aortic valve regurgitation. Two of the other 5 pa-
tients had newly ruptured chordae, 1 to the anterior leafletdiovascular Surgery c Volume 148, Number 3 1021
FIGURE 1. A, Overall survival of patients with MFS after MV surgery. Patients with MFS who underwent MV repair had 80% survival at 10-year follow-
up compared with 41% survival for patients with MFS who underwent MV replacement (P ¼ .01). B, Patients with MFS who underwent MV repair with
concomitant aortic surgery had a clinically significant better 10-year survival than patients with MFS who underwent MV replacement with concomitant
aortic surgery (64% vs 49%; P ¼ .27).
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sidual regurgitation without leaflet prolapse, and the cause
of the recurrent regurgitation in the fifth patient was indeter-
minate. Cumulative risk of reoperation 10 years postopera-
tively was 27% after MV repair versus 15% after initial
MV replacement (P ¼ .64) (Figure 2).
Matched Patient Cohort
The most common (77% [48/62]) presenting symptom in
the 62 matched patients with idiopathic myxomatous MV
disease was dyspnea. Eight percent (5/62) of the patients
presented with fatigue, ventricular tachycardia (secondary
to left ventricular hypertrophy), palpitations, or angina (sec-
ondary to coronary artery disease). Fifteen percent (9/62) of
the patients were asymptomatic. All patients in this group
(n ¼ 62) had annuloplasty (81% [50/62] posterior; 19%
[12/62] complete) as part of the valve repair, and leaflet
repair techniques included triangular or quadrangular
leaflet resection (55% [34/62]), leaflet plication (27%FIGURE 2. Cumulative risk of reoperation of patients withMFS afterMV
repair or replacement. At 10-year follow-up, patients with MFS who had
valve repair had a 27% chance of mitral reoperation, whereas patients
with MFS who had valve replacement had a 15% chance of mitral reoper-
ation (P ¼ .64).
1022 The Journal of Thoracic and Cardiovascular Sur[17/62]), neochordae insertion (15% [9/62]), and Alfieri
stitch (5% [3/62]).
The mean duration of follow-up was 6.8 (4.5) years in pa-
tients with MFS versus 5.8 (4.8) years in patients with idio-
pathic myxomatous MV disease (P ¼ .38). Survival at 10
years was similar for patients with MFS undergoing MV
repair and patients with myxomatous MV disease undergo-
ing MV repair (84% vs 78%; P ¼ .63) (Figure 3). The cu-
mulative risk of reoperation at 10 years was similar for
patients with MFS undergoing MV repair and for patients
with myxomatous MV disease undergoing MV repair
(17% vs 12%; P ¼ .61) (Figure 4).
DISCUSSION
The benefit of MV repair over replacement for patients
with severe MV regurgitation due to degenerative MV dis-
ease is well recognized. An important advantage is low
operative mortality. The present study confirms that MV
repair or replacement in MFS patients is safe. In our cohort,FIGURE 3. Overall survival of patients after MV repair. At 10-year
follow-up, patients with MFS who underwent MV repair had an 84% sur-
vival, compared with a 78% survival for patients with myxomatous MV
disease who underwent MV repair (P ¼ .63). MV, Mitral valve.
gery c September 2014
FIGURE 4. Cumulative risk of reoperation of patients after MV repair. At
10-year follow-up, patients with MFS who underwent MV repair had a
17% chance of mitral reoperation, whereas patients with idiopathic myxo-
matous MV disease who underwent valve repair had a 12% chance of
mitral reoperation (P ¼ .61). MV, Mitral valve.
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deaths since 1981. Other smaller series have reported
similar outcomes.3-5 This risk of mortality is similar to
that for the general population of patients undergoing MV
operations.6
Compared with prosthetic replacement, MV repair for
degenerative valve disease is associated with better preser-
vation of left ventricular function and improved late sur-
vival.1 Furthermore, for many patients, MV repair avoids
the need for long-term anticoagulation with warfarin. How-
ever, many patients withMFS and severeMRwill require or
will have previously undergone composite replacement of
the aortic valve and ascending aorta and may require
long-term use of warfarin for thromboembolism prophy-
laxis of the aortic prosthesis. In addition, the potential sur-
vival benefit of MV repair for patients with MFS has not
been completely established.
In our study, 10-year survival was 80% in patients with
MFS after MV repair and 41% in patients with MFS after
MV replacement. Survival estimates were not adjusted for
year of operation, and it is possible that the poorer outcome
of patients undergoing valve replacement was related, in
part, to the era of surgery. The mechanism of survival
benefit may be better preservation of systolic ventricular
function, although we could not address specific mecha-
nisms directly in our analysis. However, the difference in
late survival does not seem to be related to prosthesis-
related complications, because embolic events were infre-
quent and did not cause death.
The durability of MV repair has been questioned for pa-
tients withMFS or other connective tissue disorders. First, pa-
tients with MFS who have MV regurgitation seem to have
more frequent involvement of the anterior leaflet than patientsThe Journal of Thoracic and Carwith degenerative valve disease. In a study of MV pathology,
Bhudia and colleagues5 found that patients with MFS had
anterior and posterior leaflet prolapse almost as frequently
as patients with degenerative MV disease in whom posterior
leaflet prolapse predominates. This finding is potentially
important regarding durability, because the additional
complexity of correction of anterior leaflet prolapse may
lead to greater risk of recurrent MR late postoperatively.7
In addition, the durability of MV repair in patients with
MFS may be compromised because potentially ‘‘diseased
tissue’’ remains after repair. But a similar situation exists af-
ter repair of myxomatous MVs. Recent histologic studies
comparing patients with MFS who have MV disease with
those with myxomatous MV disease suggest similarities
in valve tissue. Both pathologic processes appear to be
associated with fibrillin abnormalities and alteration of the
transforming growth factor (TGF)-b pathway. The final
pathway of MV degeneration in patients with MFS is
thought to be mutation of fibrillin-1 protein binding to
TGF-b–activating factors.2 Nasuti and colleagues8 have
identified abnormalities in fibrillin in myxomatous valves
as evidenced by more diffuse and weaker staining for fibril-
lin than that found in normal leaflets. The myxomatous MV
with prolapse also has increased TGF-b expression.9,10
Thus, there may be common pathways of valve
degeneration in both MFS and myxomatous MV disease.
In a previous series of patients with MFS undergoing MV
surgery, Gillinov and colleagues3 reported outcomes of 36
patients (29 repairs, 7 replacements). Only 1 patient required
re-repair, necessitated by endocarditis, and no patient
required late replacement. Fuzellier and colleagues4 re-
ported on 33 patients with MFS who had MV intervention
(32 repairs, 1 replacement). Freedom fromMV regurgitation
was reported as 87% at 10 years, and no patient had more
than 2þMR during the entire follow-up period. In the pres-
ent study, the reintervention rate after valve repair in patients
with MFS was higher than in previous reports, but our series
does include the earliest repairs performed at Mayo Clinic.
We found no statistically significant difference in the dura-
bility of MV repair when patients with MFS were compared
with patients with myxomatous MV disease.
It should be noted that selection of MV repair rather than
MV replacement was influenced by other indications for
warfarin. Only 15% (n ¼ 6) of our cohort of 40 patients
with MFS who underwent MV repair had concomitant or
previous aortic valve replacement with a mechanical valve,
compared with 62% (n ¼ 13) of the 21 patients with MFS
who underwent MV replacement. However, there may be a
bias regarding the era of surgery, because many MV re-
placements were performed in the early experience of
Mayo Clinic. A potential advantage for patients undergoing
MV repair with a mechanical aortic prosthesis is a lower in-
tensity of anticoagulation with warfarin compared with that
required for patients with a mechanical MV prosthesis.diovascular Surgery c Volume 148, Number 3 1023
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The limitations to this study include its retrospective na-
ture. This cohort is also representative of our single-
institution, referral-based practice, and thus our findings
may not be generalizable. The experience reflects a practice
that evolved over 5 decades, although most patients under-
went operations in the recent era of MV repair. Finally,
although our study examined a large number of patients
with MFS who underwent MV surgery, the analysis is un-
derpowered to detect survival differences between the
subgroups.
CONCLUSIONS
To better understand survival and reintervention rates, we
case-matched patients with MFS who underwent MV repair
to patients with myxomatous MV disease who underwent
MV repair; we found no difference in survival or freedom
from reoperation. Durability and long-term survival suggest
that MV repair in patients with MFS may be preferable to
replacement, even in patients who undergo concomitant
aortic valve replacement.
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Dr Duke Cameron (Baltimore, Md). I have no disclosures. Dr
Kunkala, our thanks to you and the Mayo Clinic group for this
article, which clearly shows that MV repair has the same low oper-
ative risk and good long-term durability as in the patient without
MFS with conventional myxomatous MV disease.
My only criticism is that it probably gives an unfairly pessi-
mistic view of the long-term results of MV replacement. Most of
your MV replacement cases were still performed in the first half
of the series at a time when your patients really didn’t have the1024 The Journal of Thoracic and Cardiovascular Surbenefits of modern myocardial protection and postoperative man-
agement and our understanding of how the MV works. In 40% of
your replacements, the MV was completely excised, which is
something we would rarely do today. I wonder, if you looked at
your MV replacements that had been performed in the second
half of the series, in a modern era, are the results really as bad as
they are with the series overall?
Second, you said in the presentation that most patients with
MFS coming from MV surgery are already receiving anticoagula-
tion. I think you probably just meant to say ‘‘some.’’ Because
certainly in the era in which aortic valve-sparing surgery is
becoming so commonplace, the whole idea here is to try to keep
them off anticoagulants altogether.
My third comment regards the technique of mitral repair.
There is no question that the spectrum of MV disease in MFS is
broad, from the simplest P2 prolapse that you see in myxomatous
disease to some of the worst cases of Barlow’s that you could
imagine.
Our experience with these lesions is that the more complex the
mitral pathology, the simpler our repairs have become. You can
spend all day transferring cords and resecting leaflets, but some
of these extreme valves are best served by a ring, plus or minus
the Alfieri stitch, to prevent systolic anterior motion. This has
worked well. Can you comment on that strategy?
Dr Helder. Regarding the survival of the patients with MV
replacement, you are correct that most of these patients had
replacement in an earlier era, and this may have influenced late
outcome. But it is important to recognize that valvuloplasty tech-
niques have improved with time, and the outcome of valve repair
performed in the earlier era may not be equivalent to results today.
Regarding your comment on anticoagulation, you are correct that
in current practice many or most patients undergo valve-sparing
operations and would not require anticoagulation for an aortic
prosthesis. We agree with your strategy for using less complex
techniques for MV repair in patients with MFS and for the larger
population of patients presenting for MV repair.
Dr Pirooz Eghtesady (St Louis, Mo). I noticed on one of your
slides the overall intervention rate for the MV had increased sub-
stantially with, obviously, a larger percentage being MV repairs in
the most recent era. Is that because indications have changed?
You’re being more aggressive? How would you characterize that?
Dr Helder. I think the reason for more MV repairs is that sur-
geons are becoming more comfortable with various repair tech-
niques to address a wider variety of mitral pathologies.
Dr Scott LeMaire (Houston, Tex). Did you look at specific
valve-related complications at all, such as thromboembolism or
bleeding complications, in the 2 cohorts?
Dr Helder. Of the 21 patients who had MV replacement, 3
developed transient ischemic attacks. So in that small number, I
guess we could say that the replacement cases had a little bit
more of an embolic phenomenon than the repair cases. Otherwise,
we did not see a difference in bleeding or other embolic events in
either group because the events were fairly low to begin with.
Dr LeMaire. I may have missed it, but was there any difference
in the need for subsequent procedures on the MV in the 2 groups?
Dr Helder. There was not. There was no statistically significant
difference between MV reoperation rates between the repair and
replacement groups.gery c September 2014
